Steve Mather asserts that under the new regulatory landscape, a drug's clinical trial protocol design has effectively become its global market access strategy.

Steve Mather believes that commercial excellence at launch cannot recover value for a pharmaceutical asset if that value was not designed into the asset during its early development stages.

Pharmaceutical companies are developing modular clinical trial designs to be more flexible in accommodating the divergent evidence requirements from different European countries under the Joint Clinical Assessment (JCA).